Risk factors for high dialysate glucose use in pd patients-a retrospective 5-year cohort study

Peritoneal Dialysis International

Volumn 30, Issue 4, 2010, Pages 448-455

  Wu, Hon Yen ^a,b,c   Hung, Kuan Yu ^c   Hu, Fu Chang ^b   Chen, Yung Ming ^c   Chu, Tzong Shinn ^c   Huang, Jenq Wen ^c   Wu, Kwan Dun ^c   Tsai, Tun Jun ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Departmentof Internal Medicine   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIALYSATE LEVEL; FEMALE; GLUCOSE TOLERANCE TEST; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TAIWAN;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS; DIALYSIS SOLUTIONS; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 77957689574     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2009.00063     Document Type: Article

References (27)

1. Lameire N, Matthys D, Matthys E, Beheydt R. Effects of long-term CAPD on carbohydrate and lipid metabolism. Clin Nephrol 1988; 30(Suppl 1):S53-8.
2. Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564-7.
3. De Santo NG, Capodicasa G, Senatore R, Cicchetti T, Cirillo D, Damiano M, et al. Glucose utilization from dialysate in patients on continuous ambulatory peritoneal dialysis (CAPD). Int J Artif Organs 1979; 2:119-24.
4. Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25:415-25.
5. Wu HY, Hung KY, Huang JW, Chen YM, Tsai TJ, Wu KD. Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. Am J Nephrol 2008; 28:765-71.
6. Peng YS, Chiang CK, Hung KY, Chiang SS, Lu CS, Yang CS, et al. The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patients. Nephrol Dial Transplant 2007; 22:857-61.
7. Chaudhary K, Khanna R. Renal replacement therapy in end-stage renal disease patients with chronic liver disease and ascites: role of peritoneal dialysis. Perit Dial Int 2008; 28:113-17.
8. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
9. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67:1609-15.
10. Davies SJ, Brown EA, Reigel W, Clutterbuck E, Heimbürger O, Diaz NV, et al. What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis? Analysis of data from EAPOS. Perit Dial Int 2006; 26:458-65.
11. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
12. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33:27-39.
13. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948-57.
14. Davies SJ, Brown EA. EAPOS: what have we learned? Perit Dial Int 2007; 27:131-5.
15. Yao Q, Lindholm B, Heimbürger O. Peritoneal dialysis prescription for diabetic patients. Perit Dial Int 2005; 25(Suppl 3):S76-9.
16. Gan HB, Chen MH, Lindholm B, Wang T. Volume control in diabetic and nondiabetic peritoneal dialysis patients. Int Urol Nephrol 2005; 37:575-9.
17. Abbott KC, Oliver DK, Hurst FP, Das NP, Gao SW, Perkins RM. Body mass index and peritoneal dialysis: "exceptions to the exception" in reverse epidemiology? Semin Dial 2007; 20:561-5.
18. Aslam N, Bernardini J, Fried L, Piraino B. Large body mass index does not predict short-term survival in peritoneal dialysis patients. Perit Dial Int 2002; 22:191-6.
19. Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461-9.
20. McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2004; 24:340-6.
21. Stompór T, Sulowicz W, Dembínska-Kiéc A, Janda K, Wójcik K, Zdzienicka A. An association between body mass index and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis? Perit Dial Int 2003; 23:79-83.
22. Johnson DW, Mudge DW, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23:276-83.
23. Holmes C, Mujais S. Glucose sparing in peritoneal dialysis: implications and metrics. Kidney Int Suppl 2006; (103):S104-9.
24. Chung SH, Stenvinkel P, Bergström J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 2000; 20(Suppl 5):S57-67.
25. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006; 26:405-7.
26. Rodríguez-Carmona A, Pérez Fontán M, García López E, García Falcón T, Díaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27:260-6.
27. le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25(Suppl 3):S64-8.